Elicio Therapeutics, Inc.
ELTX
$10.60
-$0.43-3.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.09M | 2.96M | 2.77M | 3.14M | 2.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.09M | 10.74M | 13.48M | 10.34M | 10.92M |
| Operating Income | -10.09M | -10.74M | -13.48M | -10.34M | -10.92M |
| Income Before Tax | -10.56M | -11.21M | -14.00M | -18.84M | -7.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.56M | -11.21M | -14.00M | -18.84M | -7.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.56M | -11.21M | -14.00M | -18.84M | -7.23M |
| EBIT | -10.09M | -10.74M | -13.48M | -10.34M | -10.92M |
| EBITDA | -10.04M | -10.68M | -13.39M | -10.27M | -10.84M |
| EPS Basic | -0.66 | -0.87 | -1.03 | -1.39 | -0.64 |
| Normalized Basic EPS | -0.43 | -0.54 | -0.64 | -0.87 | -0.40 |
| EPS Diluted | -0.66 | -0.87 | -1.03 | -1.39 | -0.64 |
| Normalized Diluted EPS | -0.43 | -0.54 | -0.64 | -0.87 | -0.40 |
| Average Basic Shares Outstanding | 16.06M | 12.95M | 13.65M | 13.58M | 11.28M |
| Average Diluted Shares Outstanding | 16.06M | 12.95M | 13.65M | 13.58M | 11.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |